

BioDlink's Bevacizumab receives approval for market launch in Indonesia

22 August 2025 | News

Marking fourth consecutive emerging market authorisation



China's BioDlink has announced that its Bevacizumab Injection has obtained marketing authorisation from Indonesia's National Agency of Drug and Food Control (BPOM). This marks BioDlink's fourth international approval within two months – following Nigeria, Pakistan, and Colombia – signaling accelerated BioDlink's global expansion into a sustained commercialisation phase.

Indonesia, the world's fourth-most populous nation, reports over 400,000 new cancer cases annually (WHO). Yet biologics accessibility remains below 15%. As ASEAN's largest pharmaceutical market and regulatory hub, this approval expedites regional market access across Southeast Asia. BioDlink's cost-effective bevacizumab, manufactured in China in compliance with international GMP standards, is helping to address critical treatment gaps for patients in Indonesia.

Bevacizumab injection is a targeted cancer therapy used to treat various types of cancer by inhibiting blood vessel formation, thereby slowing tumour growth.

Dr Jun Liu, Chief Executive Officer and Executive Director of BioDlink, stated, "These consecutive approvals demonstrate the strength of our quality systems and commercial execution. With Indonesia as a key ASEAN hub, and in close partnership with Kexing Biopharm, we are shifting from single-market breakthroughs to regional impact —expanding access, diversifying growth, and delivering affordable, high-quality therapies worldwide."